By: Will Sansom From: uthscsa.edu UT Health San Antonio researchers have discovered a novel way to kill cancers that are caused by an inherited mutation in BRCA1, the type of cancer for which actress Angelina Jolie had preventive double mastectomy and reconstructive surgery in 2013. “This represents a new treatment for inherited breast and ovarian cancer, which are higher in …
Researchers develop early detection test for ovarian cancer
Source: Queen’s University Belfast Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches. The researchers discovered that the presence of four proteins together, known as a biomarker panel, indicates the likelihood of Epithelial Ovarian Cancer (EOC), a type of ovarian cancer. Using these biomarkers …
USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations
By: Staff Reporter From: genomeweb.com The US Preventive Services Task Force (USPSTF) has officially released its updated recommendations for BRCA-related cancer risk assessment, genetic counseling, and testing, maintaining the focus on family history that prompted reactions from patient advocate groups, testing labs, and others when the draft guidance was opened up to public commentary in February. The USPSTF — an …
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
From: PR Newswire – Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to …
UT Southwestern Researchers find evidence a cancer drug may be extended to many more patients
Source: UT Southwestern Medical Center From: PR Newswire A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers. The new study also revealed a potential biomarker indicating when …
Phase III Shows Benefit With Olaparib in Platinum-Sensitive BRCA+ Relapsed Ovarian Cancer
By: Danielle Ternyila From: targetedonc.com According to topline findings from the multicenter, open-label, phase III SOLO3 trial, the overall objective response rate (ORR) was 72% with single-agent olaparib (Lynparza) versus 51% with chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA-mutant ovarian cancer who were previously treated with at least 2 chemotherapy regimens. Further, in patients with only 2 prior lines …
Clinical trial underscores promise of immunotherapy, in combination with second drug, for ovarian cancer
From: dana-farber.org A combination of an immunotherapy drug and a DNA repair-blocking agent can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers indicates. The trial, known as TOPACIO/Keynote-162, offers compelling evidence that immunotherapies, which rarely have an impact against ovarian cancer as single …
Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
Source: Celsion CORP From: globenewswire.com Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. This Phase IB study evaluated patients newly diagnosed with Stage III/IV ovarian cancer and were treated with Celsion’s DNA-based, IL-12 immunotherapy, GEN-1, in combination …
Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial
From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …
Moving Away From IP Chemotherapy in Advanced Ovarian Cancer
By: Bradley J. Monk, MD From: onclive.com The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that …